Gene · 8717
Papers2,847
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,847
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia. | J Cancer | 2023 | 37476188 | PubTator, text mining | PubMed |
| Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides as an Important Scaffold for Anticancer Drug Discovery-In Vitro and In Silico Evaluation. | Int J Mol Sci | 2023 | 37446136 | PubTator, text mining | PubMed |
| Ferroptosis, Necroptosis, and Pyroptosis in Gastrointestinal Cancers: The Chief Culprits of Tumor Progression and Drug Resistance. | Adv Sci (Weinh) | 2023 | 37436087 | PubTator, text mining | PubMed |
| Single-cell profiling reveals distinct immune response landscapes in tuberculous pleural effusion and non-TPE. | Front Immunol | 2023 | 37435066 | PubTator, text mining | PubMed |
| Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials. | J Nanobiotechnology | 2023 | 37434199 | PubTator, text mining | PubMed |
| EDA ligand triggers plasma membrane trafficking of its receptor EDAR via PKA activation and SNAP23-containing complexes. | Cell Biosci | 2023 | 37430358 | PubTator, text mining | PubMed |
| TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma. | J Exp Clin Cancer Res | 2023 | 37415241 | PubTator, text mining | PubMed |
| Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma. | Respir Res | 2023 | 37415224 | PubTator, text mining | PubMed |
| Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines. | BMC Genomics | 2023 | 37400761 | PubTator, text mining | PubMed |
| Heterogeneity in functional genetic screens: friend or foe? | Front Immunol | 2023 | 37398651 | PubTator, text mining | PubMed |
| Molecular basis of fluoride toxicities: Beyond benefits and implications in human disorders. | Genes Dis | 2023 | 37397522 | PubTator, text mining | PubMed |
| Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery. | Pharmaceuticals (Basel) | 2023 | 37375845 | PubTator, text mining | PubMed |
| NF-κB in Cell Deaths, Therapeutic Resistance and Nanotherapy of Tumors: Recent Advances. | Pharmaceuticals (Basel) | 2023 | 37375731 | PubTator, text mining | PubMed |
| The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma. | Int J Mol Sci | 2023 | 37373484 | PubTator, text mining | PubMed |
| Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis: A Novel Therapeutic Target in Nervous System Diseases. | Int J Mol Sci | 2023 | 37373274 | PubTator, text mining | PubMed |
| The Many Faces of MLKL, the Executor of Necroptosis. | Int J Mol Sci | 2023 | 37373257 | PubTator, text mining | PubMed |
| Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells. | Biomedicines | 2023 | 37371757 | PubTator, text mining | PubMed |
| The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP. | Cells | 2023 | 37371123 | PubTator, text mining | PubMed |
| Non-Vesicular Release of Alarmin Prothymosin α Complex Associated with Annexin-2 Flop-Out. | Cells | 2023 | 37371039 | PubTator, text mining | PubMed |
| Zafirlukast Is a Promising Scaffold for Selectively Inhibiting TNFR1 Signaling. | ACS Bio Med Chem Au | 2023 | 37363080 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8717/papers?page=12